Investor's Business Daily on MSN9h
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New EntryThis pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy ...
This impressive growth was driven by strong sales of its drugs, FIRDAPSE and AGAMREE. Additionally, Catalyst has maintained a strong financial position with over $500 million in cash. The company ...
The announcement follows finalised recommendations this week that backed Agamree (vamorolone) as a treatment for patients aged four and over with DMD from the National Institute for Health and ...
This impressive growth was driven by strong sales of its drugs, FIRDAPSE and AGAMREE. Additionally, Catalyst has maintained a strong financial position with over $500 million in cash. The company's ...
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares soared to an all-time high this week, reaching a peak of $24.44. According ...
At close: 24 January at 3:00:00 pm GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback